Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A0B65S3
Mon, 01.08.2022
PAION AG
PAION Launches eravacycline for the treatment of complicated intra-abdominal infections in Adults in Germany
Eravacycline has the status as a reserve antibiotic
Providing broad-spectrum coverage against bacterial pathogens
Aachen (Germany), 01 August 2022 – The Specialty Pharma Company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchan [ … ]
Mon, 01.08.2022
PAION AG
PAION Launches eravacycline for the treatment of complicated intra-abdominal infections in Adults in Germany
Eravacycline has the status as a reserve antibiotic
Providing broad-spectrum coverage against bacterial pathogens
Aachen (Germany), 01 August 2022 – The Specialty Pharma Company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchan [ … ]
Fri, 24.06.2022
PAION AG
PAION REPORTS SOLID PROGRESS WITH COMMERCIAL ACTIVITIES IN EUROPE
- Product rollouts in UK, Netherlands and Scandinavia going well, including formulary acceptance
- Positive customer feedback following initial experience with PAION products
Aachen (Germany), 24 June 2022 – The specialty pharma company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock [ … ]
Wed, 25.05.2022
PAION AG
PAION AG: ANNUAL GENERAL MEETING APPROVES ALL AGENDA ITEMS AND ELECTS MICHAEL SCHLENK AND GREGOR SIEBERT TO THE SUPERVISORY BOARD
- Agenda items approved with a large majority
- Michael Schlenk and Gregor Siebert elected as successors to Dr Dr Antonijevic and Dr Jörg Spiekerkötter; Dr Hans Christoph Tanner re-elected
Aachen (Germany), 25 May 202 [ … ]
Wed, 18.05.2022
PAION AG
PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST QUARTER OF 2022
- Transformation into commercial specialty pharma company continues
- Financial position strengthened to support commercial activities in Europe by sale of Chinese remimazolam patents and future royalties to Humanwell for EUR 20.5 million
- Expansion of partner networ [ … ]
Wed, 30.03.2022
PAION AG
PAION AG ANNOUNCES CHANGE IN MANAGEMENT BOARD
- Sebastian Werner to succeed Abdelghani Omari as Chief Financial Officer
- New CFO of PAION AG with many years of experience at international pharmaceutical companies
Aachen (Germany), 30 March 2022 - The specialty pharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime [ … ]
Wed, 30.03.2022
PAION AG
PAION AG REPORTS ON FISCAL YEAR 2021
- Transformation into commercial specialty pharma company following expansion of European product portfolio; own commercialisation of remimazolam, angiotensin II and eravacycline started in second half of 2021
- Remimazolam launched by partners in U.S. and South Korea
- Financial position strengthened to [ … ]
Thu, 27.01.2022
PAION AG
PAION AG ANNOUNCES CHANGE IN SUPERVISORY BOARD
Michael Schlenk to succeed Dr. Dr. Irina Antonijevic and to become candidate for the chairmanship of the Supervisory Board
Aachen (Germany), 27 January 2022 - The specialty pharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today announces that the Sup [ … ]
Fri, 31.12.2021
PAION AG
PAION SUBMITS EXTENSION APPLICATION OF MARKETING AUTHORIZATION FOR REMIMAZOLAM IN THE INDICATION GENERAL ANESTHESIA TO THE EUROPEAN MEDICINES AGENCY
Aachen (Germany), 31 December 2021 - The Specialty Pharma Company PAION AG (FSE: PA8) today announces that PAION has submitted an extension application to the Marketing Authorization for remimazolam [ … ]
Wed, 10.11.2021
PAION AG
PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2021
- Transformation into commercial specialty pharma company following expansion of European product portfolio; angiotensin II (GIAPREZA(R)) and eravacycline (XERAVA(R)) successfully launched in Q3 2021
- PAION launches remimazolam (Byfavo(R)) in the UK and the Netherland [ … ]